Four-year follow-up results from the Phase 3 CheckMate 9DW trial show that nivolumab plus ipilimumab continues to provide sustained overall survival and durable response benefits versus lenvatinib or sorafenib as first-line therapy for unresectable hepatocellular carcinoma. The combination demonstrated higher long-term survival rates and a higher complete response rate, with no new safety signals reported.